Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

The researchers found that after 64 weeks, participants had a mean weight loss of −16.7%, with a mean semaglutide dose of 1.08mg/week.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Despite the rising popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, many still prefer drug-free ...

A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

FuturHealth offers both compounded semaglutide and FDA-approved name-brand options like Wegovy and Ozempic. For most users, ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide ...

Incretin mimetics are revolutionizing obesity treatment, but high prices and supply shortages limit patient access. Some clinicians have suggested less frequent dosing as an off-ramping strategy to ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of ...

Some say that Ozempic can lead to surprise pregnancies, referred to as "Ozempic babies," by increasing fertility. Learn what ...